On February 5, 2026, President Donald J. Trump announced the launch of TrumpRx.gov. The White Hiouse Fact Sheet states, "Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price)."
Category Archives: AZBio News
New Health Policy Included Federal Government Funding Package
When President Trump signed H.R. 7148, the Consolidated Appropriations Act, 2026, it did more than end the four-day partial shutdown. The Act also includes a number of reauthorizations and new policies that have been advocated by patients, healthcare professions, and innovative healthcare companies. Continue reading
Precision Epigenomics Receives CAP Accreditation, Advancing Commitment to Quality and Clinical Excellence
Achieving CAP accreditation is a significant milestone for Precision Epigenomics”— Joshua Routh, MD, Medical Director of Precision EpigenomicsContinue reading
Long Awaited Legislation on Multi Cancer Early Detection Tests for Medicare Beneficiaries Becomes Law
On February 3, 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law, establishing Medicare coverage for blood-based Multi-Cancer Early Detection (MCED) tests. Continue reading
Modernizing the National Institutes of Health: Faster Discoveries, More Cures
Hon. Jayanta Bhattacharya, M.D., Ph.D., Director, National Institutes of Health testified in the Senate Health Education, and Pensions Committee on February 3, 2026. The hearing, titled “Modernizing the National Institutes of Health: Faster Discoveries, More Cures” focused on the vital role of the NIH in our nation’s health innovation leadership on the global stage.Continue reading
Building the Life Sciences Workforce of the Future
The Life Sciences Workforce Collaborative (LSWC) launched its first LSWC Best Workforce Strategies Roundtable on January 30, 2026 with opening remarks from Caitlin Frazer, Executive Director of the National Security Commission on Emerging Biotechnology (NSCEB).Continue reading
Tracking U.S. Biopharma Investment: New Resources Detail State-by-State Impact
America’s biopharmaceutical sector is delivering unprecedented economic impact across the nation. Since January 2025, companies have committed more than $582 billion to bolster U.S. research and development, expand manufacturing and create jobs in communities nationwide.From cutting-edge manufacturing facilities in the South to next-generation research hubs in the Mid-Atlantic, the life sciences industry is driving local economic growth, creating high-skill jobs and ensuring Americans have faster access to breakthrough medicines.Continue reading
Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development
Phoenix, AZ, January 29, 2026 (Globe Newswire): Breakthru Medicine emerges from stealth mode with the close of a $60M Series A financing round following a prior undisclosed seed round.
Breakthru was founded by biotech industry veterans Steve Potts, PhD, Mark Mulvihill, PhD, and Brian Barnett, MD, to deliver disruptive therapeutic modalities to cancer patients to address major unmet medical needs.Continue reading
BioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial -Tissue Regeneration Solutions
PHOENIX, Jan. 27, 2026 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix‑based medical manufacturer specializing in advanced wound protection technologies, has announced a strategic investment in Imbed Biosciences, Inc., the Wisconsin‑based medical device innovator behind the fully-synthetic SAM™ Antimicrobial Technology, and Microlyte®, the wound matrix based on SAM™ Technology.Continue reading
CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs
Negotiations Will Occur in 2026 With Negotiated Prices Effective in 2028Continue reading